Helix BioMedix, Inc. (HXBM)

OTCMKTS · Delayed Price · Currency is USD
6.45
-0.73 (-10.17%)
At close: Jun 10, 2025
-72.28%
Market Cap1.45M
Revenue (ttm)2.07M
Net Income (ttm)-2.58M
Shares Out224.71K
EPS (ttm)-15.59
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume142
Average Volume235
Open6.45
Previous Close7.18
Day's Range6.45 - 6.45
52-Week Range6.45 - 23.50
Beta0.56
RSI19.22
Earnings Daten/a

About Helix BioMedix

Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1988
Employees 8
Stock Exchange OTCMKTS
Ticker Symbol HXBM
Full Company Profile

Financial Performance

In 2011, Helix BioMedix's revenue was $1.89 million, an increase of 122.07% compared to the previous year's $851,683. Losses were -$2.49 million, -67.73% less than in 2010.

Financial Statements

News

There is no news available yet.